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Abstract The P2Y2 receptor is a G-protein-coupled recep-
tor with adenosine 5′-triphosphate (and UTP) as natural
ligands. It is thought to be involved in bone physiology in
an anti-osteogenic manner. As several non-synonymous sin-
gle nucleotide polymorphisms (SNPs) have been identified
within the P2Y2 receptor gene in humans, we examined
associations between genetic variations in the P2Y2 receptor
gene and bone mineral density (BMD) (i.e., osteoporosis
risk), in a cohort of fracture patients. Six hundred and ninety
women and 231 men aged ≥50 years, visiting an osteopo-
rosis outpatient clinic at Maastricht University Medical
Centre for standard medical follow-up after a recent frac-
ture, were genotyped for three non-synonymous P2Y2 re-
ceptor gene SNPs. BMD was measured at three locations
(total hip, lumbar spine, and femoral neck) using dual-
energy X-ray absorptiometry. Differences in BMD between
different genotypes were tested using analysis of covari-
ance. In women, BMD values at all sites were significantly
different between the genotypes for the Leu46Pro
polymorphism, with women homozygous for the variant
allele showing the highest BMD values (0.05>p>0.01).
The Arg312Ser and Arg334Cys polymorphisms showed
no differences in BMD values between the different geno-
types. This is the first report that describes the association
between the Leu46Pro polymorphism of the human P2Y2
receptor and the risk of osteoporosis.
Keywords P2Y2 receptor . Osteoporosis . Bone mineral
density . Polymorphisms
Introduction
Osteoporosis is a condition of the skeleton characterized by
decreased bone density and bone structure changes, reduc-
ing its strength and resulting in increased risk of fragility
fractures. This bone disease is one of the most common
health problems among elderly in the Western society. In
Europe, approximately 30 % of women and 12 % of men
aged over 50 suffer from osteoporosis [1].
Due to the growing elderly population as well as the
sedentary lifestyle and changes in nutritional habits, the
incidence of osteoporosis and related fractures is expected
to increase exponentially worldwide over the next decades.
In terms of human capital losses as well as use of health care
resources, this will lead to an enormous social economical
burden. The annual cost of osteoporotic fractures nowadays
is suggested to be approximately 36 billion euros [2] and is
anticipated to increase to 106 billion euros in 2050
(www.iofbonehealth.org).
Bone remodeling is the process responsible for maintain-
ing bone quality during life. In this process, bone tissue is
continuously renewed by tight regulation of the balance
between bone resorption by osteoclasts and bone formation
by osteoblasts [3]. The underlying mechanisms responsible
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for regulating the balance between bone resorption and
formation are currently not fully understood. However, it
has become more and more clear that purinergic signaling
plays an essential role in this process [4]. Purinergic signal-
ing is dependent on binding of nucleotides to specific so-
called purinergic receptors. These purinergic receptors can
be divided in two major receptor subclasses, namely, P1 and
P2 receptors, according to their distinct affinities for aden-
osine and ATP/ADP, respectively [5]. The P2 receptor sub-
class can be further subdivided in P2X receptors, of which
seven subtypes are known (P2X1, 2, 3, 4, 5, 6, 7), and P2Y
receptors, of which eight subtypes are known (P2Y1, 2, 4, 6,
11, 12, 13, 14) [6]. Expression of several of the P2X and P2Y
receptor subtypes by different bone cell types has been
demonstrated (reviewed in [7]).
The P2Y2 receptor is fully activated by ATP and UTP [8]
and is expressed in a variety of tissues in the human body
where it plays important roles in various processes by acti-
vation of phospholipase C β and subsequent generation of
inositol (1, 4, 5)-trisphosphate, which leads to a rise in
calcium and activation of protein kinase C [9]. The expres-
sion of the P2Y2 receptor on human bone cells was first
reported by Bowler et al. [10], who found that P2Y2 recep-
tor DNA was expressed by human osteoblasts derived from
bone explants. This finding was later confirmed by another
group [11]. Osteoblast-like cells from the human osteosar-
coma cell lines MG-63 and OHS-4 have also been shown to
express the P2Y2 receptor [12]. In addition to expression by
osteoblasts, expression of the P2Y2 receptor on osteoclasts
has been observed in osteoclasts derived from a human giant
cell tumor of a bone [10].
Different authors have shown that the P2Y2 receptor is
involved in the bone biology [13–15]. In vitro experiments
showed that ATP and UTP at concentrations of 1–10 μM, but
not adenosine and ADP, strongly inhibited mineralized bone
nodule formation by cultured rat osteoblasts [13], which was
suggested to involve either P2Y2 or P2Y4 receptors. Later
studies demonstrated that a P2Y4 antagonist failed to prevent
the above nucleotide-induced inhibition of mineralization,
suggesting that activation of the P2Y2 receptor was responsi-
ble for the observed functional effects of ATP and UTP on
osteoblast-mediated bone formation [16]. In agreement with
these findings, Orriss and colleagues [15] showed that ATP
and UTP (but not ADP and UDP) inhibited the expression and
activation of alkaline phosphatase. Animal studies using a
P2Y2 knock-out model confirmed the putative anti-
osteogenic effect of the P2Y2 receptor. Mice lacking the
P2Y2 receptor showed a 9 % increase in bone mineral content
of the femora and a 17 % increase in BMC of the tibiae
compared to wild-type mice [15]. However, in contrast to
these anti-osteogenic findings, Katz and colleagues [17]
showed in osteoblastic cells up-regulation of the P13/Akt
signal transduction pathway by extracellular ATP, which is
important in growth and survival of osteoblasts [18]. Since
both the P2Y2 agonists ATPγS and UTP showed increased
Akt phosphorylation, the authors suggested that the P2Y2
receptor is responsible for this P13/Akt up-regulation, leading
to osteoblastic proliferation.
The above data make the P2Y2 receptor gene a possible
candidate gene in the causation of osteoporosis. Based on
this, we hypothesized that single nucleotide polymorphisms
(SNPs) in the P2Y2 receptor resulting in aberration of re-
ceptor function would affect bone mineral density (BMD) in
humans.
Dasari et al. (1996) first mapped the P2Y2 receptor gene
to the human chromosome 11q13.5-14.1, spanning over
18 kb coding for 377 amino acids and consisting of three
exons separated by two introns (Fig. 1). This receptor is
known to have three splice variants. To date, over 100 SNPs
have been reported within the P2Y2 receptor gene according
to the international Hapmap project, of which at least three
non-synonymous SNPs lead to an amino acid change
(Fig. 1). Two of these three non-synonymous SNPs have
known effects on P2Y2 receptor function, leading to a gain-
of-receptor function [19, 20]. For the Arg334Cys polymor-
phism, it was shown that carriers of the 334Cys mutation
produced slower accumulation of intracellular inositol tri-
phosphates and had a significantly increased transient Ca2+
influx compared to wild-type [19, 20]. Subjects homozy-
gous for the Arg312Ser polymorphism showed an increased
transient Ca2+ influx compared to wild-type cells [20]. The
functional effect of the other non-synonymous SNP (Leu46-
Pro) has not yet been established.
In the present study, we investigated the presence and
frequency of three non-synonymous P2Y2 gene polymor-
phisms in a Dutch cohort of fracture patients and analyzed
whether genetic variation in this purinergic receptor was
associated with altered BMD, i.e., osteoporosis risk. We
chose a fracture cohort as this is characterized by the high
prevalence of osteoporosis [21].
Methods
Study population and design
The study base for the present study consisted of men and
women aged ≥50 years, who visited an osteoporosis outpa-
tient clinic at the Maastricht University Medical Centre
(MUMC+), the Netherlands, for standard medical care fol-
lowing a recent fracture. Fracture patients suffering from a
disease of bone metabolism other than osteoporosis (e.g.,
Paget disease, bone tumors, and hyperparathyroidism) were
excluded from participation.
The study was approved by the ethical committee of the
University Hospital Maastricht and Maastricht University,
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and all participants signed written informed consent after
having received proper information about the study before
performing any of the study procedures. Participants for the
present study were recruited at the osteoporosis outpatient
clinic at MUMC+ among patients receiving regular medical
follow-up for a recent fracture. The regular medical follow-
up procedure for fracture patients was as follows [21]:
1. Patients, who presented with a clinical fracture at the
emergency unit or were hospitalized because of a frac-
ture, were invited to the fracture and osteoporosis out-
patient clinic;
2. During a first consultation, usually 2–6 weeks following
the fracture, besides receiving information about the
outpatient clinic and possible treatment regimes,
patients were asked to undergo a bone densitometry;
3. During a second consultation, usually 2–4 weeks later,
BMD measurement was performed by dual X-ray
absorptiometry (DXA) and, in addition, risk factors for
falls and osteoporosis were assessed; if indicated, me-
dicinal treatment for osteoporosis was started according
to the Dutch osteoporosis guideline recommendation.
For the present study, we recruited subjects from the
above-mentioned population of fracture patients by using
two different procedures: first, between August 2008 and
December 2009, blood was collected from patients who
visited the osteoporosis outpatient clinic. All patients re-
ceived extensive oral and written information about the
study during their first consultation; then, during their sec-
ond consultation, written informed consent was obtained,
and blood samples were collected and stored at −80 °C for
subsequent DNA extraction and genotyping.
Second, to increase statistical power, saliva was collected
from fracture patients who had formerly visited the osteo-
porosis outpatient clinic before August 2008. Eligible
patients for this recruitment procedure were identified using
an existing patient database of the osteoporosis outpatient
clinic at MUMC+, which had been initiated in September
2004. All eligible patients received an information package
by mail, which included (1) a letter to inform patients about
the present study, (2) a standard device to collect saliva
together with instructions for its use, (3) an informed con-
sent form, and (4) a return envelope with pre-printed ad-
dress. Patients willing to participate were asked to sign the
informed consent form, to donate a small amount of saliva,
and to send both of these back to us in the return envelope.
Patients, from whom no reaction was received within
2 weeks after the information package had been sent, were
contacted once by telephone to increase the response rate.
DNA extraction
Blood samples
DNA was extracted from blood in an automated proce-
dure using Maxwell 16 DNA purification kits on the
Maxwell 16 instrument (Promega, Madison, WI); 400 μl
of blood collected in EDTA tubes were used and the
isolation procedure was performed according to the
manufacturer's instructions.
Saliva samples
For collection of a small amount of saliva for DNA
extraction, we used a SalivetteTM (Sarstedt AG & Co.
Numbrecht, Germany), a plastic vial containing a small
cotton roll that needs to be chewed on for 45–60 s,
yielding approximately 1.5 ml of saliva and is then
placed back into the plastic vial. Patients were asked
to use the Salivette at least 30 min after eating, drink-
ing, or use of oral medication. Upon return, the Sali-
vetteTM containing the saliva swab was stored in a
refrigerator at 4 °C until DNA extraction. First, the
swab kept in the collection tube was centrifuged at
4,000 rpm for 10 min, and the saliva was transferred
to a 15-ml Nunc tube which was kept at 5 °C over-
night. Using a pair of sterile tweezers, the swab was
then transferred from the collection tube to a 50-ml
Nunc tube; 4 ml sterile water was added and the tube
was kept at room temperature overnight. The next day,
the swab plus water was transferred back into the col-
lection tube and again centrifuged at 4,000 rpm for
10 min; the saliva yield was again transferred to the
15-ml Nunc tube already containing the saliva yield
from the day before. Next, cells were isolated from
the saliva by centrifuging the saliva-containing 15-ml
Nunc tube at 4,000 rpm for 10 min. Subsequently, the
supernatant was carefully removed, leaving 600–800 μl
over the pellet. DNA extraction was then carried out
using Maxwell 16 DNA purification kits on the Max-
well 16 instrument (Promega, Madison, WI) according
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Genotyping
The study population was genotyped for three non-
synonymous SNPs within the P2Y2 receptor gene that were
selected based on their previously published functional
effects on the P2Y2 receptor or were found in the dbSNP
database for non-synonymous SNPs (Fig. 1). Genotyping
was done by Sequenom (Sequenom, Hamburg, Germany)
using the Sequenom MassARRAY ® iPLEX Gold assay,
which uses PCR amplification followed by a single base
pair primer extension reaction, resulting in an allele specific
difference in mass between extension products. This mass
difference allows the data analysis software to differentiate
between SNP alleles using matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry.
Internal validation study
To assess the accuracy of the genotyping assay, an internal
validation study was performed in which a randomly select-
ed number of samples (N045) were genotyped a second
time, using restriction enzyme digestion of appropriate PCR
products or Taqman assay. This was done according to a
previously published protocol (Hansen et al. 2008). When
the results were compared with the original genotyping, we
observed a discrepancy between the two different genotyp-
ing methods of ~4.2 %. The discrepancy appeared to be
smaller (~2.7 %) if the original genotyping with the Seque-
nom MassARRAY ® iPLEX Gold assay had failed for
maximum of one SNP. Therefore, all subjects in whom the
original genotyping had failed for at least two SNPs were
excluded from statistical analysis.
Bone density measurements
As part of the standard medical follow-up of fracture
patients, BMD (in grams per cubic centimeter) of the lumbar
spine (L2–L4), femoral neck, and total hip (trochanter and
neck) was assessed by DXA, using the cross-calibrated
Hologic QDR 4500 Elite densitometer (Waltham, Massa-
chusetts, USA). This was usually done 4–10 weeks follow-
ing the fracture, before starting medicinal treatment in case
osteoporosis was diagnosed. BMD T score values were used
to establish the presence or absence of osteoporosis (T≤−2.5)
and osteopenia (−2.5<T<−1).
Statistical analysis
Distribution of genotype frequencies was tested for Hardy–
Weinberg equilibrium (HWE) by chi-square test. Descriptive
statistics were used to determine the prevalence of osteoporo-
sis and osteopenia in the cohort of fracture patients, as well as
to assess distributions of possible risk factors, including sex,
age (in years), bodymass index (BMI, in kilograms per square
centimeter), previous fracture (yes/no), and family history of
fractures (yes/no), which were all recorded during a patient's
second consultation at the osteoporosis outpatient clinic. Fur-
thermore, descriptive statistics were used to describe the oc-
currence of different fracture types.
Differences in BMD between the genotypes for each
individual SNP were tested for significance by using the
general linear model procedure for covariance analysis
(ANCOVA) after testing for normal distribution of the data
and uniformity of variances. Preliminary analyses showed
that only sex, age, and BMI were associated with several
SNPs. Therefore, all analyses were stratified by sex and
adjusted for age and BMI.
The frequency of all possible haplotype combinations
was investigated, and differences in BMD between the most
frequent haplotype combinations were tested for signifi-
cance using the general linear model procedure for
ANCOVA. As a confirmatory approach, we used propor-
tional odds logistic regression to estimate the influence of
P2Y2 receptor genotypes on the odds of a low BMD T score
value and thus on osteoporosis risk. For this approach,
quintiles of the population were defined based on BMD T
score values. The proportional odds assumption was tested
using the chi-square score test.
For all analyses, p values<0.05 were considered statisti-




Of the 630 patients with a recent fracture, who were invited to
the osteoporosis outpatient clinic between August 2008 and
December 2009, 467 (74.1 %) were willing to undergo a bone
densitometry. Of these fracture patients, during their second
consultation at the osteoporosis outpatient clinic, 394 (84.4 %)
were willing to donate blood. The collection of blood failed
for 13 (3.3 %) patients and genotyping for 5 (1.3 %) patients
(Fig. 2), leaving 376 patients included for analysis.
Of the 2,975 fracture patients who had formerly visited
the osteoporosis outpatient clinic between September 2004
and August 2008, 2,122 (71.3 %) had undergone a bone
densitometry. Two hundred thirty of these patients had died
in the meantime (10.8 %). Of the 1,892 former fracture
patients who were invited by mail to participate in the pres-
ent study, 1,064 (58.2 %) gave consent and returned saliva
samples. DNA extraction failed for 27 (2.5 %) samples and
genotyping for 492 (46.2 %) samples (based on the outcome
of an internal validation study) (Fig. 2), leaving 545 patients
included for analysis.
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Characteristics of the 921 participants are listed in
Tables 1 and 2. The final study population consisted of
690 women aged 65.5±9.8 years (mean±SD) and 231
men aged 63.5±9.6 years. The prevalence of osteoporosis
was 32.2 % among women and 26.4 % among men, and the
prevalence of osteopenia was 48.0 % among women and
42.0 % among men. Hip fractures and fractures of the
humerus were most common among subjects suffering from
osteoporosis (11.8 and 15.7 %, respectively), whereas other
common osteoporotic fractures, i.e., fractures of the lumbar
spine and wrist, were more frequent in subjects suffering
from osteopenia (4.8 and 29.7 %, respectively). No differ-
ences were observed between the data collected during the
two recruitment procedures. Furthermore, no differences in
baseline characteristics were observed between subjects in-
cluded in the analyses and subjects excluded based on the
internal validation study.
P2RY2 genotypes
Minor allele frequency and information on Hardy–Weinberg
equilibrium of the three genotyped non-synonymous SNPs
within the P2Y2 receptor gene are shown in Table 3. The
Arg312Ser was found to be in HWE, but both Leu46Pro and
Arg334Cys showed significant deviation fromHWE (p<0.05).
Association of P2Y2 receptor genotypes with bone mineral
density
In women, BMD values at the lumbar spine and femoral
neck were significantly different between the genotypes for
the Leu46Pro polymorphism, with women homozygous for
the variant allele showing the highest BMD values (p00.03
and 0.01, respectively). BMD values at the total hip were
borderline significantly higher in women homozygous for
the variant allele (p00.05) (Table 4). The proportional odds
logistic regression confirmed these results by showing that
the odds of a lower T score (i.e., the risk of osteoporosis)
was significantly decreased by approximately 30–40 % in
women homozygous for the variant allele compared to the
other two genotypes at the lumbar spine and femoral neck
(lumbar spine OR00.66 [95 % CI, 0.46–0.95]; femoral neck
OR00.59 [95 % CI, 0.40–0.86]) (Fig. 3). Although, both the
Arg312Ser and Arg334Cys polymorphisms showed de-
creased BMD values in women homozygous for the variant
allele, none of these differences were statistically signifi-
cant. In men, no association between the different genotypes
of each SNP and BMD values could be observed.
Association of P2Y2 receptor haplotypes with bone mineral
density
The seven most common haplotype combinations were test-
ed for association with bone mineral density, that is TGG/
TGG (H1), TGG/TCG (H2), TGG/TGA (H3), TGG/CGG
(H4), TGG/TCA (H5), TGG/CCG (H6), and TCG/TCG
(H7). This analysis included 591 women and 200 men and
Fig. 2 Flow chart of patient recruitment for the present study. Single
asterisk number of patients recruited during phase 1 between August
2008 and December 2009. Double asterisks number of patients
recruited during phase 2 between January and July 2010
Table 1 Characteristics of the
study population








Age (years) 65.0 (9.8) 63.5 (9.6) 65.5 (9.8)
Weight (kg) 72.5 (13.8) 82.29 (12.4) 69.2 (12.6)
Height (cm) 165.8 (9.1) 175.7 (7.3) 162.5 (6.9)
BMI (kg/m2) 26.3 (4.2) 26.6 (3.7) 26.2 (4.4)
Femoral neck BMD (g/cm2) 0.69 (0.13) 0.76 (0.13) 0.66 (0.12)
Total hip BMD (g/cm2) 0.84 (0.15) 0.95 (0.15) 0.80 (0.13)
Lumbar spine BMD (g/cm2) 0.93 (0.17) 0.98 (0.17) 0.91 (0.17)
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covered over 93 % of the total population. As shown in
Table 5, in both women and men, the wild-type combination
of the three SNPs (i.e., wild-type for each of the three
polymorphisms, TGG/TGG) was the most frequent haplo-
type (31.2 and 34.0 %, respectively).
No statistically significant differences were found be-
tween the common haplotype combinations and BMD val-
ues adjusted for age and BMI (Table 5). However, women
heterozygous for the Leu46Pro (TC genotypes, i.e., haplo-
types H4 and H6) showed increased BMD values at the
lumbar spine compared to women wild-type for the Leu46-
Pro polymorphism (i.e., haplotypes H1–H3, H5, and H7)
(BMDLS00.93–0.94 vs 0.89–0.91, respectively). Haplotype
H6, which, besides Leu46Pro, also includes individuals
heterozygous for the Arg334Lys SNP (GC), also showed
increased BMD values at the hip, compared to haplotypes in
which women were wild-type for the Leu46Pro polymor-
phism (i.e., haplotypes H1–H3, H5, and H7) (BMDTH00.83
vs 0.76–0.81 BMDFN00.71 vs 0.64–0.67, respectively).
Using a model in which haplotypes H1–H3, H5, and H7
were combined, this increase in femoral neck BMD was
statistically significant (p00.04).
Discussion
Within a cohort of Dutch fracture patients, we have
shown that the Leu46Pro polymorphism in the P2Y2
receptor gene was associated with increased BMD val-
ues in women, i.e., decreased risk of osteoporosis. This
result is consistent with our main hypothesis that genet-
ic aberration of P2Y2 receptor function affects BMD in
humans. However, both the Arg334Cys and Arg312Ser
polymorphisms had no significant relationship with
BMD in human.
This is the first study demonstrating an association
between the Leu46Pro polymorphism and osteoporosis
risk. Women homozygous for the variant allele of the
Leu46Pro polymorphism had significantly increased
BMD values and a decreased risk of osteoporosis. So
far, no in vitro studies have established the effect of this
polymorphism on P2Y2 receptor function as well as on
bone cell function. Since in vitro experiments and ani-
mal studies failed to clarify whether the P2Y2 receptor
plays an anti- or pro-osteogenic role in bone, it remains
unclear at present whether the Leu46Pro polymorphism
is a loss- or gain-of-function SNP. Cell studies on the
functional effect of this polymorphism are therefore
warranted.
The Arg334Cys and Arg312Ser polymorphisms had
no significant relationship with BMD in our study pop-
ulation. Both these polymorphisms have been shown to
increase P2Y2 receptor function in vitro, as cells homo-
zygous for the variant allele showed significantly in-
creased transient Ca2+ influx compared to wild-type
cells [19, 20]. Our findings showed that women homo-
zygous for the variant allele of the Arg334Cys or
Arg312Ser polymorphism had decreased BMD values
compared to women carrying at least one wild-type
allele, though not statistically significant. Recently
Table 2 Prevalence of osteopo-
rosis and osteopenia in the study
population, and distribution of
fractures
aOsteoporosis defined by BMD
T score values, T≤−2,5
bOsteopenia defined by BMD T
score values, −2.5<T<−1
Osteoporosisa Osteopeniab Normal BMD
% (N) % (N) % (N)
Total study population (N0921) 30.7 (283) 46.5 (428) 22.8 (210)
Men (N0231) 26.4 (61) 42.0 (97) 31.6 (73)
Women (N0690) 32.2 (222) 48.0 (331) 19.8 (137)
Type of fracture
Humerus (N0108) 15.7 (40) 11.6 (46) 11.2 (22)
Femur (N072) 11.8 (30) 8.3 (33) 4.6 (9)
Lumbar spine (N038) 4.3 (11) 4.8 (19) 4.1 (8)
Wrist (N0206) 24.8 (63) 29.7 (118) 12.7 (25)
Other fracture (N0424) 43.3 (110) 45.6 (181) 67.5 (133)
Table 3 List of P2Y2 receptor SNPs for which the study population was genotyped
rs number Base change Polymorphism MAF HWE p value Effect
rs2511241 137C>T Leu46Pro 0.09 0.012 n.a..
rs3741156 936G>C Arg312Ser 0.23 0.120 Gain-of-receptor function
rs1626154 1000C>T Arg334Cys 0.16 0.031 Gain-of-receptor function
MAF minor allele frequency, HWE Hardy–Weinberg equilibrium, n.a. not available (no data published on functional effects of this polymorphism)
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published preliminary data from a Danish cohort con-
sisting of 2,016 early postmenopausal women, however,
showed that women homozygous for the variant allele
of the Arg312Ser polymorphisms had significantly in-
creased hip BMD at menopause (mean BMD±SEM,
0.94 g/cm2±0.012 (p00.017)) compared to women with
wild-type allele (0.92 g/cm2±0.004) after correction for
age and logBMI. Furthermore, they found that women
with wild-type allele had almost 25 % higher rate of
bone loss at the lumbar spine at both 5 and 10 years
after menopause than women homozygous for the vari-
ant allele (respectively: 5 years, −1.23 and −1.01 % per
year (p00.008); 10 years, −0.76/−0.62 % per year (p0
0.028)) [22]. Therefore, larger association studies will
be needed to elucidate the association between the
Arg312Ser polymorphisms and BMD values.
Table 4 BMD values for the
individual genotypes for each
single SNP
p values are shown for statistical
analysis of covariance
(ANCOVA) for the bone mineral
density (BMD) parameters ad-
justed for age and BMI. Numb-
ers are means (SD)
LS lumbar spine, FN femoral
neck, TH total hip
aAdjusted for age and BMI
SNP WT HET HOMO p valuea
Woman
Leu46Pro TT TC CC
N 569 100 11
BMD TH (g/cm2) 0.79 (0.13) 0.81 (0.14) 0.83 (0.13) 0.054
BMD LS (g/cm2) 0.90 (0.16) 0.93 (0.17) 0.99 (0.17) 0.026
BMD FN (g/cm2) 0.66 (0.12) 0.68 (0.12) 0.70 (0.14) 0.013
Arg312Ser GG GC CC
N 398 236 41
BMD TH (g/cm2) 0.80 (0.13) 0.81 (0.14) 0.76 (0.13) 0.073
BMD LS (g/cm2) 0.91 (0.17) 0.91 (0.16) 0.90 (0.18) 0.926
BMD FN (g/cm2) 0.66 (0.11) 0.67 (0.12) 0.65 (0.11) 0.352
Arg334Cys GG GA AA
N 483 157 23
BMD TH (g/cm2) 0.80 (0.13) 0.80 (0.14) 0.78 (0.13) 0.844
BMD LS (g/cm2) 0.91 (0.17) 0.91 (0.17) 0.90 (0.16) 0.947
BMD FN (g/cm2) 0.67 (0.11) 0.66 (0.12) 0.64 (0.12) 0.843
Men
Leu46Pro TT TC CC
N 188 39 3
BMD TH (g/cm2) 0.94 (0.15) 0.98 (0.15) 0.90 (0.12) 0.479
BMD LS (g/cm2) 0.98 (0.17) 1.00 (0.17) 0.88 (0.13) 0.429
BMD FN (g/cm2) 0.76 (0.13) 0.77 (0.13) 0.71 (0.10) 0.775
Arg312Ser GG GC CC
N 145 67 15
BMD TH (g/cm2) 0.95 (0.16) 0.96 (0.14) 0.88 (0.16) 0.732
BMD LS (g/cm2) 0.97 (0.16) 1.00 (0.19) 0.97 (0.16) 0.462
BMD FN (g/cm2) 0.76 (0.13) 0.76 (0.13) 0.73 (0.14) 0.960
Arg334Cys GG GA AA
N 153 63 8
BMD TH (g/cm2) 0.95 (0.14) 0.93 (0.17) 1.04 (0.16) 0.158
BMD LS (g/cm2) 0.99 (0.17) 0.95 (0.16) 1.00 (0.17) 0.272
BMD FN (g/cm2) 0.76 (0.13) 0.75 (0.14) 0.79 (0.16) 0.863
Fig. 3 Graphical display of the risk on low BMD T score value of
women carrying at least one wild-type allele of the Leu46Pro poly-
morphism (TT and TC genotypes) compared to women homozygous
for the variant allele (CC genotype) at the total hip (TH), lumbar spine
(LS), and femoral neck (FN)
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The analysis of haplotypes showed that women car-
rying the variant allele of both the Leu46Pro and
Arg312Ser polymorphisms had increased BMD values
at all sites. As the analyses of individual SNPs showed
increased BMD values in women carrying at least one
variant allele of the Leu46Pro, whereas women carrying
at least one variant allele of the Arg312Ser showed
decreased BMD values, it can be speculated that a
presumed loss of P2Y2 receptor function due to the
presence of the Leu46Pro polymorphism has a dominant
positive effect on BMD if expressed together with the
variant allele of the Arg312Ser polymorphism.
It should be noted that, although the allele frequen-
cies of the studied non-synonymous SNPs in our popu-
lation were comparable to previously published data
[19, 20, 22], both the Leu46Pro and Arg334Cys poly-
morphisms showed significant deviation from HWE.
Therefore, studies in different populations are needed
to confirm our findings.
Our study has several limitations. One limitation is
the possibility of false negative findings due to lack of
power, as is the case in many other genetic association
studies. A second limitation of our study was that we
did not have access to reliable information on other risk
factors for osteoporosis, such as vitamin D and calcium
intake, physical activity, and years since menopause, so
that our analyses could not be adjusted for these factors.
However, unlike classical epidemiological studies, ge-
netic association studies are unlikely to be confounded
by behavioral and environmental factors as these factors
are very unlikely to show an association with the geno-
type. We therefore think that confounding by these risk
factors or other unmeasured factors was not an issue.
Nevertheless, the lack of adjustment might have influ-
enced the precision of our results. Furthermore, explo-
ration of the presence of gene–environment interactions
was limited by the lacking information on certain oste-
oporosis risk factors.
We deliberately chose a fracture cohort with high preva-
lence of osteoporosis to investigate the associations between
P2Y2 SNPs and osteoporosis risk for reasons of efficiency.
Although it is a limitation that this cohort is not population
based, it should be noted that for genetic screening purpo-
ses, such a high-risk population is considered more relevant
than a general population.
Recently performed genome-wide-association studies
(GWAS) have confirmed many previously identified
candidate genes for osteoporosis, such as LRP5, OPG,
RANK, and RANKL [23], and polymorphisms affecting
the expression of these gene products have implications
on bone mass and strength. However, the effect sizes
are relatively small in a polygenetic trait such as BMD.
Nevertheless, current GWAS studies are best powered
for SNPs with a population frequency in the range of
10–90 %. Therefore, relatively rare polymorphisms such
as the Leu46Pro polymorphism, which has a population
frequency around 9 % in Caucasian, would likely have
been missed in GWAS studies.
In conclusion, this is the first study describing an associ-
ation between the Leu46Pro polymorphism in the P2Y2
receptor gene and BMD, supporting a role for this gene in
the regulation of human bone mass. More studies are war-
ranted to elucidate the exact role of the P2Y2 receptor in the
bone physiology.

















N (%) 198 (31.2) 146 (23.0) 96 (15.1) 43 (6.8) 37 (5.8) 35 (5.5) 36 (5.7)
BMD TH (g/cm2) 0.80 (0.13) 0.81 (0.14) 0.80 (0.14) 0.78 (0.11) 0.78 (0.13) 0.83 (0.16) 0.76 (0.13) 0.149
BMD LS (g/cm2) 0.90 (0.17) 0.91 (0.16) 0.91 (0.17) 0.93 (0.12) 0.90 (0.16) 0.94 (0.19) 0.89 (0.17) 0.731
BMD FN (g/cm2) 0.66 (0.11) 0.67 (0.12) 0.66 (0.11) 0.66 (0.10) 0.64 (0.12) 0.71 (0.13) 0.64 (0.11) 0.115
Men
N (%) 68 (34.0) 37 (18.5) 41 (20.5) 16 (8.0) 13 (6.5) 13 (6.5) 12 (6)
BMD TH (g/cm2) 0.95 (0.15) 0.95 (0.12) 0.91 (0.18) 0.99 (0.15) 0.96 (0.17) 0.97 (0.15) 0.89 (0.18) 0.910
BMD LS (g/cm2) 0.98 (0.17) 1.02 (0.20) 0.93 (0.14) 1.02 (0.17) 0.98 (0.17) 0.97 (0.18) 0.98 (0.15) 0.385
BMD FN (g/cm2) 0.76 (0.13) 0.75 (0.12) 0.74 (0.13) 0.79 (0.15) 0.81 (0.17) 0.78 (0.12) 0.73 (0.16) 0.903
p values are shown for analysis of covariance (ANCOVA) for the bone mineral density (BMD) parameters with age and BMI as covariates.
Numbers are means (SD)
LS lumbar spine, FN femoral neck, TH total hip
a TGG/TGG indicates wild-type for Leu46Pro (TT), Arg312Ser (GG), and Arg334Cys (GG)
b Adjusted for age and BMI
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